BMAL1 and neoplasm: Tang et al. have proved that BMAL1 in TSCC is a potential marker at the time of paclitaxel administration, and they showed that PER2 is a marker for tumor clinical stage and risk of metastasis as well as an ideal candidate for novel targets in the prevention and treatment of oral cancer (Tang et al., 2019) (Figure 4; Table 1).